Members of FDA’s Vaccine and Related Biological Products Advisory Committee endorsed Pfizer and BioNTech’s Covid-19 vaccine candidate on Thursday, clearing the last hurdle before emergency use authorization from the federal agency.
The committee, also called VRBPAC, met for nine hours to discuss all aspects of the new Covid-19 vaccine, from risk and safety to how Pfizer and BioNTech plan on monitoring future clinical trials.
The committee generally agreed that the vaccine was safe and effective in people aged 16 and up, and that the benefits of a new vaccine for Covid-19 outweigh the potential risks.
Read the full article.
BREAKING. Advisory Committee to @US_FDA votes to authorize @pfizer emergency use application (#EUA) for its #mRNA vaccine against #SARSCoV2, the virus that causes #COVID19. We now await an official decision by the FDA. @CBSEveningNews @CBSThisMorning @CBSSunday @60Minutes pic.twitter.com/SrJaQBBRAC
— Jonathan LaPook, M.D (@DrLaPook) December 10, 2020